Neurochemical predictors of response to pharmacologic treatments for bipolar disorder

被引：16

作者：

DelBello M.P. ^{[1
]}

Strakowski S.M. ^{[1
]}

机构：

[1] Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267

来源：

Current Psychiatry Reports | 2004年 / 6卷 / 6期

关键词：

Lithium; Bipolar Disorder; Magnetic Resonance Spectroscopy; Biol Psychiatry; Bipolar Patient;

D O I：

10.1007/s11920-004-0012-1

中图分类号：

学科分类号：

摘要：

Bipolar disorder is a common psychiatric disorder that is characterized by recurrent episodes of mania and often depression. Mood stabilizers and antipsychotics are first-line pharmacologic options for patients with bipolar disorder. However, the exact mechanisms by which these medications exert the mood stabilizing effects are unknown. Additionally, individuals with bipolar disorder often try several medications unsuccessfully before achieving mood stabilization. Magnetic resonance spectroscopy (MRS) is a noninvasive neuroimaging technique that can be used to identify the neurochemical effects and predictors of response to medications commonly used to treat bipolar disorder. MRS may facilitate targeted treatment interventions and decrease the morbidity and mortality associated with this illness. Examining the mechanisms of action of pharmacologic agents used to treat bipolar disorder may clarify the neurophysiologic basis of bipolar disorder. We will review recent MRS investigations that have evaluated the neurochemical effects of pharmacologic treatments and predictors of treatment response in patients with bipolar disorder. Copyright © 2004 by Current Science Inc.

引用

页码：466 / 472

页数：6

共 58 条

[41]

Lafer B., Renshaw P.F., Sachs G., Et al., Proton MRS of the basal ganglia in bipolar patients, Biol. Psychiatry, 35, (1994)

[42]

Silverstone P.H., Hanstock C.C., Rotzinger S., Lithium does not alter the choline/creatine ratio in the temporal lobe of human volunteers as measured by proton magnetic resonance spectroscopy, J. Psychiatry Neurosci., 24, pp. 222-226, (1999)

[43]

Stoll A.L., Sachs G.S., Cohen B.M., Et al., Choline in the treatment of rapid-cycling bipolar disorder: Clinical and neurochemical findings in lithium treated patients, Biol. Psychiatry, 40, pp. 382-388, (1996)

[44]

Lyoo I.K., Demopulos C.M., Hirashima F., Et al., Oral choline decreases brain purine levels in lithium-treated subjects with rapid cycling bipolar disorder: A double-blind trial using proton and lithium magnetic resonance spectroscopy, Bipolar Disord., 5, pp. 300-306, (2003)

[45]

Michael N., Erfurth A., Ohrmann P., Et al., Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex, Psychopharmacology, 168, pp. 344-346, (2003)

[46]

Dager S.R., Friedman S.D., Parow A., Et al., Brian metabolic alterations in medication-free patients with bipolar disorder, Arch. Gen. Psychiatry, 61, pp. 450-458, (2004)

[47]

Castillo M., Kwock L., Courvoisie H., Et al., Proton MR spectroscopy in children with bipolar affective disorder: Preliminary observations, Am. J. Neuroradiol., 21, pp. 832-838, (2000)

[48]

Preece N.E., Gadian D.G., Houseman J., Et al., Lithium-induced modulation of cerebral inositol phosphate metabolism in the rat: A multinuclear magnetic resonance study in vivo, Lithium, 3, pp. 287-297, (1992)

[49]

Kato T., Inubushi T., Kato N., Prediction of lithium response by 31P-MRS in bipolar disorder, Int. J. Neuropsychoparmacol., 3, pp. 83-85, (2000)

[50]

Renshaw P.F., Schnall M.D., Leigh Jr. J.S., In vivo 31P NMR spectroscopy of agonist-stimulated phosphatidylinositol metabolism in cat brain, Magn. Reson. Med., 4, pp. 221-226, (1987)

← 1 2 3 4 5 6 →